Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer

The androgen receptor (AR) is a critical driver of prostate cancer (PCa). Here, to study regulators of AR protein levels and oncogenic activity, we developed a live-cell quantitative endogenous AR fluorescent reporter. Leveraging this AR reporter, we performed genome-scale CRISPRi flow cytometry sorting screens to systematically identify genes that modulate AR protein levels. We identified and validated known AR protein regulators, including HOXB13 and GATA2, and also unexpected top hits including PTGES3-a poorly characterized gene in PCa. PTGES3 repression resulted in loss of AR protein, cell-cycle arrest and cell death in AR-driven PCa models. Clinically, analysis of PCa data demonstrates that PTGES3 expression is associated with AR-directed therapy resistance. Mechanistically, we show PTGES3 binds directly to AR, regulates AR protein stability and is necessary for AR function in the nucleus at AR target genes. PTGES3 represents a potential therapeutic target for overcoming known mechanisms of resistance to existing AR-directed therapies in PCa.

Authors

Institutions

Publication Details

Journal
Nature Genetics
Published
2025-11-05
DOI
https://doi.org/10.1038/s41588-025-02388-8
Citations
2
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
3.04

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer

Emily A. Egusa, Becky Xu Hua Fu, Hyun Jin Shin, Siyu Feng et al.
2 citations
Nature Genetics
Prostate Cancer Treatment and Research
3.04
article

Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer

Emily A. Egusa, Becky Xu Hua Fu, Hyun Jin Shin, Siyu Feng, Eric Jay Small, J. A. Anderson, Elai Davicioni, Humberto J. Suarez, Seema Nath, Jonathan Chou, Bo Huang, Felix Yi-Chung Feng, Rajdeep Das, Mohammed Alshalalfa, William S. Chen, Luke A. Gilbert, Raunak Shrestha, Martin Sjöström, Bradley A. Stohr, David A. Quigley, James E. Melnyk, Audrey Kishishita, Arun P. Wiita, Lisa N. Chesner, Meng Zhang, Jun Zhu, Peter S. Nelson, Elizabeth V. Wasmuth, Haolong Li, Wanting Han, Kevan M. Shokat, Abhilash Barpanda, Tatyanah Farsh, Tianyi Liu, Junjie T. Hua, Ashutosh Maheshwari, Marsha Calvert, Javed Siddiqui
article en
2 citations

Abstract

The androgen receptor (AR) is a critical driver of prostate cancer (PCa). Here, to study regulators of AR protein levels and oncogenic activity, we developed a live-cell quantitative endogenous AR fluorescent reporter. Leveraging this AR reporter, we performed genome-scale CRISPRi flow cytometry sorting screens to systematically identify genes that modulate AR protein levels. We identified and validated known AR protein regulators, including HOXB13 and GATA2, and also unexpected top hits including PTGES3-a poorly characterized gene in PCa. PTGES3 repression resulted in loss of AR protein, cell-cycle arrest and cell death in AR-driven PCa models. Clinically, analysis of PCa data demonstrates that PTGES3 expression is associated with AR-directed therapy resistance. Mechanistically, we show PTGES3 binds directly to AR, regulates AR protein stability and is necessary for AR function in the nucleus at AR target genes. PTGES3 represents a potential therapeutic target for overcoming known mechanisms of resistance to existing AR-directed therapies in PCa.

Nature GeneticsVol. 57(12)
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa (ZA), Howard Hughes Medical Institute (US), Emory University (US), The University of Texas at San Antonio Health Science Center (US), University of California, San Francisco (US), Lund University (SE), University of Michigan (US), American Research Center in Egypt (US), Fred Hutch Cancer Center (US), University of California San Francisco Medical Center (US), Veracyte (United States) (US), Chan Zuckerberg Initiative (United States) (US), Palo Alto Institute (US), UCSF Helen Diller Family Comprehensive Cancer Center (US), Arc Research Institute
U.S. Department of Defense, Howard Hughes Medical Institute, Prostate Cancer Foundation, Cancer Prevention and Research Institute of Texas, Cancerfonden, Vetenskapsrådet, Svenska Läkaresällskapet, National Institutes of Health, University of California, San Francisco, Stand Up To Cancer, National Cancer Institute, DOD Prostate Cancer Research Program
Openalex Percentile: Top 7%
Prostate Cancer Treatment and Research
3.04
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.